ArticleNeurochemical research2026
Potential Role of Zn Supplementation in Ameliorating Reserpine-Induced Fibromyalgia Manifestations Through Central NLRP3-Autophagy-Redox Network Modulation in Rats.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia is a chronic disorder of hyperalgesia and fatigue among other debilitating manifestations. Current antidepressant-based therapy is hampered by suboptimal tolerability. The main pathomechanism is central sensitization that is largely precipitated by glial neuroinflammation involving NLRP3 inflammasome pathway. Administration of Zn, a relatively tolerable and accessible mineral with established antioxidant and autophagy-promoting properties, was shown effective against fatigue syndromes and NLRP3 inflammasome activation, yet its effect on fibromyalgia remains elusive. The current study investigated the ameliorative efficacy of Zn administration against reserpine-induced fibromyalgia in rats. Sprague-Dawley male rats were randomized into four groups: normal control, reserpine (1 mg/kg, S.C.)-induced fibromyalgia model, and two groups receiving Zn gluconate (30 mg/kg, I.P.) daily either for a week post-induction or for a week pre- and post-induction. Zn administration alleviated reserpine-induced thermal allodynia (P < 0.0001), fatigue, and depression, but not weight loss or reduced food intake. Moreover, Zn reversed reserpine-mediated central neurodegeneration, glial activation (P < 0.01), and NLRP3 inflammasome upregulation as evidenced by significant decline in NF-κB/NLRP3/GSDMD/IL-1β and IL-18 axis with NLRP3 protein level at P < 0.01. Connectedly, Zn showed marked antioxidant and pro-autophagic effects through attenuating reserpine-induced MDA elevation (P < 0.05), total antioxidant capacity decline, Nrf2/HO-1 axis downregulation, and LC3-II: p62 balance reduction (P < 0.001). Post-treatment conferred superior histological protection, while pre-and-post-treatment provided better behavioral outcomes, NLRP3 expression decline, and redox improvements. In conclusion, this study suggests a potential role of Zn supplementation in amelioration of and protection against FM manifestations through controlling central NLRP3-autophagy-oxidative stress network, yet the potentially context- and exposure-dependent effects of Zn warrant further investigations.
Indexed as
Identifiers
42878974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.